Subgroup analysis by HER2 expression from phase 1/2 trial of patients with HER3 expressing metastatic breast cancer highlighted in a second Presidential Session
Proposed combination enhances Pfizer’s position as a leading company in oncology
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
With this additional route of administration, the MMRV Family now joins other routinely recommended vaccines that can be administered intramuscularly
Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development.
Clinical studies are expected to start in Q2 2023.
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Subscribe To Our Newsletter & Stay Updated
